China's National Medical Products Administration (NMPA) has awarded a drug registration approval to Sihuan Pharmaceutical Holdings Group (HKG:0460) unit Huisheng Biopharmaceutical's insulin degludec and insulin aspart injection.
The drug is indicated for the treatment of adult type 2 diabetes, according to a Tuesday filing on the Hong Kong bourse.
The medicine offers better glycemic control, a higher glycated hemoglobin rate, and a lower risk of hypoglycemia, the company said.
Shares of the company rose by about 8% in recent trading.
Price (HKD): $0.54, Change: $+0.04, Percent Change: +8.00%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments